ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
ZEVRA THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$10.16+0.22 (+2.21%)
Close on Oct 19, 2026
- Market cap
- $623.18M
- P/E (TTM)
- 10.9
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
78.5%
47M of 59M shares
Institutional holders
157
29 new, 17 sold out
Net institutional buying
5M
In Q2 2026
Insider trades, 12 months
0 buys · 12 sales
Net sold $2.30M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Abigail P. Johnson | 4,915,717 | 8.30% | 13G (passive) amendment | Jun 30, 2026 |
| Woodline Partners LP | 4,785,771 | 8.10% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 4,080,420 | 7.60% | 13G (passive) amendment | Dec 31, 2024 |
| Phillip Gross | 3,650,000 | 6.84% | 13G (passive) | Dec 31, 2024 |
| FMR LLC | 3,211,877 | 5.50% | 13G (passive) | Mar 31, 2026 |
| Vanguard Capital Management | 3,024,980 | 5.11% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ZVRA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 5,108,871 | 8.60% | $73.26M | +652,395 | 0.00% |
| FMR LLC | 4,915,717 | 8.28% | $70.49M | +1,703,840 | 0.00% |
| Woodline Partners LP | 4,785,771 | 8.06% | $68.63M | +1,334,828 | 0.21% |
| Nantahala Capital Management, LLC | 3,594,952 | 6.05% | $51.55M | +1,073,016 | 0.86% |
| Vanguard Capital Management LLC | 2,638,910 | 4.44% | $37.84M | +169,582 | 0.00% |
| State Street Corp | 1,681,999 | 2.83% | $24.12M | +120,430 | 0.00% |
| Geode Capital Management, LLC | 1,540,936 | 2.59% | $22.10M | +169,079 | 0.00% |
| D. E. Shaw & Co., Inc. | 1,306,949 | 2.20% | $18.74M | +460,492 | 0.01% |
| Qube Research & Technologies Ltd | 1,241,343 | 2.09% | $17.80M | +399,024 | 0.02% |
| Morgan Stanley | 1,203,875 | 2.03% | $17.26M | +11,613 | 0.00% |
| Legal & General Group Plc | 1,201,668 | 2.02% | $17.23M | +38,578 | 0.00% |
| Dimensional Fund Advisors LP | 958,836 | 1.61% | $13.75M | +404,034 | 0.00% |
| Royce & Associates LP | 882,658 | 1.49% | $12.66M | −106,016 | 0.10% |
| 683 Capital Management, LLC | 855,000 | 1.44% | $12.26M | −120,000 | 0.60% |
| Kingdon Capital Management, L.L.C. | 775,000 | 1.31% | $11.11M | – | 1.14% |
| Retirement Planning Co of New England, Inc. | 634,410 | 1.07% | $9.10M | −16,738 | 3.27% |
| Jupiter Topco LLC | 613,403 | 1.03% | $8.80M | New | 0.00% |
| Arrowstreet Capital, Limited Partnership | 597,162 | 1.01% | $8.56M | New | 0.00% |
| Goldman Sachs Group Inc | 545,551 | 0.92% | $7.82M | −197,573 | 0.00% |
| Vanguard Portfolio Management LLC | 541,109 | 0.91% | $7.76M | +74,806 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 157 | 47M | 78.5% | 29 / 65 | 40 / 17 | 11M | 6M |
| Q1 2026 | 148 | 41M | 69.6% | 18 / 53 | 53 / 26 | 10M | 4M |
| Q4 2025 | 159 | 38M | 64.2% | 23 / 59 | 53 / 29 | 6M | 8M |
| Q3 2025 | 166 | 40M | 68.0% | 56 / 52 | 37 / 10 | 12M | 8M |
| Q2 2025 | 120 | 36M | 61.1% | 24 / 44 | 30 / 13 | 5M | 4M |
| Q1 2025 | 110 | 35M | 59.8% | 16 / 44 | 28 / 13 | 5M | 3M |
| Q4 2024 | 109 | 34M | 57.1% | 25 / 41 | 19 / 23 | 8M | 3M |
| Q3 2024 | 108 | 29M | 48.8% | 28 / 36 | 20 / 12 | 16M | 3M |
| Q2 2024 | 93 | 18M | 31.1% | 15 / 42 | 14 / 11 | 5M | 1M |
| Q1 2024 | 89 | 14M | 23.8% | 12 / 22 | 37 / 6 | 2M | 3M |
| Q4 2023 | 84 | 15M | 25.7% | 14 / 35 | 11 / 7 | 5M | 0M |
| Q3 2023 | 77 | 11M | 18.2% | 12 / 25 | 16 / 6 | 3M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ZVRA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Contrafund | 2,943,298 | 4.96% | $42.21M | 0.02% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,899,706 | 3.20% | $27.24M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,524,549 | 2.57% | $21.86M | 0.03% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 679,907 | 1.14% | $9.75M | 0.01% | Jun 30, 2026 |
| Janus Henderson Small/Mid Cap Growth Alpha ETF | 670,077 | 1.13% | $6.37M | 0.61% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 644,248 | 1.08% | $6.13M | 0.02% | Jul 31, 2026 |
| Fidelity Contrafund K6 | 629,808 | 1.06% | $9.03M | 0.02% | Jun 30, 2026 |
| iShares Biotechnology ETF | 411,688 | 0.69% | $5.90M | 0.06% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 377,126 | 0.64% | $5.41M | 0.04% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 369,377 | 0.62% | $5.30M | 1.24% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 292,045 | 0.49% | $3.38M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 286,183 | 0.48% | $3.32M | 0.02% | May 31, 2026 |
| Royce Small-Cap Fund | 262,646 | 0.44% | $3.77M | 0.18% | Jun 30, 2026 |
| Janus Henderson Small Cap Growth Alpha ETF | 250,702 | 0.42% | $2.38M | 0.66% | Jul 31, 2026 |
| iShares Micro-Cap ETF | 196,894 | 0.33% | $2.82M | 0.19% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Neil F. McFarlane | President and CEO, Director | 387,225 | 0.65% | Feb 10, 2026 |
| Rahsaan Thompson | Chief Legal & Compliance | 37,569 | 0.06% | Aug 17, 2026 |
| Timothy J. Sangiovanni | SVP, Finance & Corp Controller | 29,590 | 0.05% | May 29, 2026 |
| Justin A. Renz | CFO | – | – | Mar 19, 2026 |
| Joshua Schafer | CCO | 62,278 | 0.10% | Feb 4, 2026 |
| Adrian W. Quartel | Chief Medical Officer | 14,256 | 0.02% | Feb 2, 2026 |
| Corey Michael Watton | Director | 1,800 | 0.00% | Aug 12, 2026 |
| Thomas Anderson | Director | 20,000 | 0.03% | Jun 18, 2026 |
| Tamara A. Favorito | Director | 3,894 | 0.01% | Jun 18, 2026 |
| Alicia Secor | Director | – | – | Jun 18, 2026 |
| Alvin Shih | Director | 20,000 | 0.03% | Jun 18, 2026 |
| Douglas W. Calder | Director | – | – | Jun 18, 2026 |
| John B. Bode | Director | 123,400 | 0.21% | Mar 26, 2026 |
| Wendy L. Dixon | Director | – | – | May 30, 2025 |
| R. LaDuane Clifton | – | 192,028 | 0.32% | Jan 7, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Rahsaan Thompson Chief Legal & Compliance | Aug 14, 2026 | Sale(10b5-1 plan) | −42,666 | $11.13 | $474.87K | 37,569 |
| Corey Michael Watton Director | Aug 10, 2026 | Sale | −12,300 | $11.25 | $138.38K | 1,800 |
| Corey Michael Watton Director | Aug 10, 2026 | Option exercise | +12,300 | $4.97 | $61.13K | 14,100 |
| Rahsaan Thompson Chief Legal & Compliance | Jun 22, 2026 | Sale(10b5-1 plan) | −34,557 | $12.68 | $438.18K | 80,235 |
| Rahsaan Thompson Chief Legal & Compliance | Jun 21, 2026 | Option exercise | +66,667 | – | – | 114,792 |
| Rahsaan Thompson Chief Legal & Compliance | May 11, 2026 | Sale(10b5-1 plan) | −1,794 | $11.30 | $20.27K | 48,125 |
| John B. Bode Director | Mar 24, 2026 | Option exercise | +39,200 | $4.89 | $191.69K | 123,400 |
| John B. Bode Director | Mar 24, 2026 | Option exercise | +39,200 | $4.97 | $194.82K | 84,200 |
| Neil F. McFarlane President and CEO, Director | Feb 9, 2026 | Sale(10b5-1 plan) | −14,625 | $8.56 | $125.19K | 387,225 |
| Neil F. McFarlane President and CEO, Director | Feb 7, 2026 | Option exercise | +37,500 | – | – | 401,850 |
| Timothy J. Sangiovanni SVP, Finance & Corp Controller | Feb 3, 2026 | Sale(10b5-1 plan) | −3,000 | $9.18 | $27.54K | 29,590 |
| Joshua Schafer CCO | Feb 3, 2026 | Sale(10b5-1 plan) | −10,500 | $9.19 | $96.50K | 62,278 |
| Neil F. McFarlane President and CEO, Director | Feb 2, 2026 | Sale(10b5-1 plan) | −91,000 | $9.38 | $853.58K | 364,350 |
| Joshua Schafer CCO | Jan 31, 2026 | Option exercise | +35,334 | – | – | 72,778 |
| Neil F. McFarlane President and CEO, Director | Jan 31, 2026 | Option exercise | +233,334 | – | – | 455,350 |
| Timothy J. Sangiovanni SVP, Finance & Corp Controller | Jan 31, 2026 | Option exercise | +11,666 | – | – | 32,590 |
| Joshua Schafer CCO | Jan 30, 2026 | Sale(10b5-1 plan) | −3,375 | $8.83 | $29.80K | 37,444 |
| Joshua Schafer CCO | Jan 30, 2026 | Option exercise | +11,333 | – | – | 40,819 |
| Rahsaan Thompson Chief Legal & Compliance | Jan 30, 2026 | Option exercise | +11,333 | – | – | 53,999 |
| Rahsaan Thompson Chief Legal & Compliance | Jan 30, 2026 | Sale(10b5-1 plan) | −4,080 | $8.83 | $36.03K | 49,919 |
| Timothy J. Sangiovanni SVP, Finance & Corp Controller | Jan 30, 2026 | Option exercise | +6,333 | – | – | 22,674 |
| Timothy J. Sangiovanni SVP, Finance & Corp Controller | Jan 30, 2026 | Sale(10b5-1 plan) | −1,750 | $8.82 | $15.44K | 20,924 |
| Adrian W. Quartel Chief Medical Officer | Jan 30, 2026 | Option exercise | +11,333 | – | – | 14,256 |
| Adrian W. Quartel Chief Medical Officer | Jan 30, 2026 | Sale(10b5-1 plan) | −4,533 | $8.83 | $40.03K | 9,723 |
| R. LaDuane Clifton – | Dec 31, 2025 | Option exercise | +140,667 | – | – | 192,028 |
| R. LaDuane Clifton – | Dec 31, 2025 | Tax withholding | −48,513 | $8.96 | $434.68K | 143,515 |
| Neil F. McFarlane President and CEO, Director | Oct 10, 2025 | Sale(10b5-1 plan) | −19,500 | $10.82 | $210.99K | 222,016 |
| Neil F. McFarlane President and CEO, Director | Oct 10, 2025 | Option exercise | +50,000 | – | – | 241,516 |
| Tamara A. Favorito Director | Sep 12, 2025 | Buy | +3,175 | $7.79 | $24.73K | 3,894 |
| Alvin Shih Director | Sep 12, 2025 | Buy | +20,000 | $7.89 | $157.80K | 20,000 |
| John B. Bode Director | Aug 19, 2025 | Buy | +5,000 | $9.17 | $45.85K | 45,000 |
| Rahsaan Thompson Chief Legal & Compliance | Jun 26, 2025 | Sale(10b5-1 plan) | −24,000 | $9.21 | $221.04K | 42,666 |
| Rahsaan Thompson Chief Legal & Compliance | Jun 21, 2025 | Option exercise | +66,666 | – | – | 66,666 |
| Corey Michael Watton Director | Mar 28, 2025 | Buy | +300 | $7.84 | $2.35K | 1,800 |
| John B. Bode Director | Mar 19, 2025 | Buy | +10,000 | $7.96 | $79.60K | 40,000 |
| Neil F. McFarlane President and CEO, Director | Feb 14, 2025 | Sale(10b5-1 plan) | −30,544 | $8.05 | $245.88K | 191,516 |
| Neil F. McFarlane President and CEO, Director | Feb 13, 2025 | Sale(10b5-1 plan) | −61,273 | $7.86 | $481.61K | 222,060 |
| R. LaDuane Clifton CFO & Treasurer | Feb 13, 2025 | Sale(10b5-1 plan) | −11,000 | $7.86 | $86.46K | 51,361 |
| Joshua Schafer CCO & EVP, Bus. Development | Feb 13, 2025 | Sale(10b5-1 plan) | −10,500 | $7.86 | $82.53K | 29,486 |
| Timothy J. Sangiovanni SVP, Finance & Corp Controller | Feb 13, 2025 | Sale(10b5-1 plan) | −3,000 | $7.86 | $23.58K | 16,341 |
| Joshua Schafer CCO & EVP, Bus. Development | Jan 31, 2025 | Option exercise | +35,333 | – | – | 39,986 |
| R. LaDuane Clifton CFO & Treasurer | Jan 31, 2025 | Option exercise | +43,333 | – | – | 62,361 |
| Neil F. McFarlane President and CEO, Director | Jan 31, 2025 | Option exercise | +233,333 | – | – | 283,333 |
| Timothy J. Sangiovanni SVP, Finance & Corp Controller | Jan 31, 2025 | Option exercise | +11,666 | – | – | 19,341 |
| Corey Michael Watton Director | Oct 11, 2024 | Buy | +500 | $7.92 | $3.96K | 1,500 |
| R. LaDuane Clifton CFO & Treasurer | Jul 17, 2024 | Buy | +2,000 | $6.77 | $13.54K | 18,469 |
| Thomas Anderson Director | Jul 16, 2024 | Buy | +10,000 | $6.81 | $68.10K | 20,000 |
| John B. Bode Director | Jul 12, 2024 | Buy | +10,000 | $5.87 | $58.70K | 30,000 |
| R. LaDuane Clifton CFO, Secretary & Treasurer | Sep 6, 2023 | Buy | +1,000 | $4.96 | $4.96K | 15,309 |
| Thomas Anderson Director | Sep 6, 2023 | Buy | +10,000 | $4.88 | $48.80K | 10,000 |
| Joshua Schafer CCO & EVP, Bus. Development | Sep 5, 2023 | Buy | +500 | $5.13 | $2.57K | 3,500 |
| John B. Bode Director | Sep 5, 2023 | Buy | +10,000 | $5.13 | $51.30K | 20,000 |
| Corey Michael Watton Director | Jun 23, 2023 | Buy | +275 | $5.95 | $1.64K | 1,000 |
| Corey Michael Watton Director | Jun 9, 2023 | Buy | +325 | $5.52 | $1.79K | 725 |
| Corey Michael Watton Director | May 30, 2023 | Buy | +400 | $5.11 | $2.04K | 400 |
| Joshua Schafer CCO & EVP, Bus. Development | May 19, 2023 | Buy | +1,000 | $5.42 | $5.42K | 3,000 |
| John B. Bode Director | May 18, 2023 | Buy | +2,451 | $5.05 | $12.38K | 10,000 |
| John B. Bode Director | May 18, 2023 | Buy | +100 | $5.05 | $505 | 7,549 |
| John B. Bode Director | May 18, 2023 | Buy | +4,759 | $5.04 | $23.99K | 7,449 |
| John B. Bode Director | May 18, 2023 | Buy | +1,000 | $5.04 | $5.04K | 2,690 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| F. McFarlane Neil Director, Officer | Oct 13, 2026 | 20,000 | $227.80K | Oct 12, 2026 | Restricted Stock Units |
| Thompson Rahsaan Officer, Secretary | Aug 14, 2026 | 42,666 | $477.01K | Aug 14, 2026 | Restricted Stock Units |
| Bode John Director | Jul 8, 2026 | 10,516 | $156.16K | Jul 8, 2026 | Stock Option Exercise |
| Thompson Rahsaan Officer, Chief Legal & Compliance / Secretary | May 11, 2026 | 36,351 | $404.59K | May 11, 2026 | Restricted Stock Units |
| L. Clifton Raymond Officer | Mar 16, 2026 | 345,428 | $3.41M | Mar 16, 2026 | Restricted stock vesting under a registered plan |
| F. McFarlane Neil Director, Officer | Feb 2, 2026 | 105,625 | $950.63K | Feb 2, 2026 | Restricted Stock Units |
| Quartel Adrian Officer | Jan 30, 2026 | 4,533 | $40.16K | Jan 30, 2026 | Restricted Stock Units |
| Schafer Joshua Officer | Jan 30, 2026 | 13,875 | $122.93K | Jan 30, 2026 | Restricted Stock Units |
| Thompson Rahsaan Officer, Secretary | Jan 30, 2026 | 4,080 | $36.15K | Jan 30, 2026 | Restricted Stock Units |
| LaDuane Clifton R Former CFO & Treasurer | Jan 30, 2026 | 14,000 | $124.04K | Jan 30, 2026 | Restricted Stock Units |
| Sangiovanni Timothy Officer | Jan 30, 2026 | 4,750 | $42.09K | Jan 30, 2026 | Restricted Stock Units |
| F. McFarlane Neil Director, Officer | Oct 10, 2025 | 19,500 | $210.99K | Oct 10, 2025 | Restricted Stock Units |
| Thompson Rahsaan Officer, Secretary | Jun 26, 2025 | 24,000 | $223.92K | Jun 26, 2025 | Restricted Stock Units |
| F. McFarlane Neil Director, Officer | Feb 13, 2025 | 91,817 | $708.83K | Feb 13, 2025 | Restricted Stock Units |
| Schafer Joshua Officer | Feb 13, 2025 | 10,500 | $81.06K | Feb 13, 2025 | Restricted Stock Units |